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Summary 
Interleukin 2 (IL-2) stimulated activation of the 42-kD extracellular signal-regulated kinase 2 
(Erk2) in murine IL-3-dependent cells, expressing either high or intermediate affinity IL-2 receptors. 
Activation was both rapid, occurring within 5 min of IL-2 addition, and prolonged, remaining 
elevated  for 30 min. Activation of Erk2 appeared to be necessary  for IL-2 stimulation of proliferation, 
as deletion of a region of the cytoplasmic domain of the IL-2 receptor ~  chain,  essential for 
IL-2 stimulation of proliferation,  abolished Erk2 activation by IL-2. Furthermore, cells that had 
been deprived of cytokine for 24 h were then refractory to IL-2 stimulation of both Erk2 activity 
and proliferation. However, elevation of Erk2 activity was not sufficient to stimulate proliferation, 
as protein kinase C activation stimulated Erk2 activity but not DNA synthesis. Also, cells exposed 
to IL-2 in the presence of rapamycin showed full Erk2 activation but not DNA synthesis. These 
data suggest  that IL-2 must stimulate  both Erk2 activity and a further pathway(s)  to trigger 
cell proliferation. 
I 
L-2 is a polypeptide growth factor  secreted by antigen- 
activated helper T lymphocytes, which stimulates prolifer- 
ation and effector functions of a variety of cells of the im- 
mune system (1). IL-2 interacts with cell surface receptors, 
composed of at least three cell surface proteins, to stimulate 
cells. High affinity receptors are formed from p55 ol chains, 
p75 3 chains, and p64 3' chains, whereas intermediate affinity 
receptors consist of 3  and 3' chains (2). IL-2 occupancy of 
either high (3), or intermediate (4) affinity receptors can stimu- 
late cell proliferation.  Two regions of the cytoplasmic do- 
main of the IL-2 receptor 3 chain have been shown by muta- 
tional analysis to be important for stimulation of proliferation. 
Deletion of a serine-rich region (amino acids 267-322) results 
in a receptor that fails to stimulate immediate early gene ex- 
pression (5) or proliferation  (6) when expressed in an IL-3- 
dependent cell. An acidic domain (amino acids 313-382) is 
required for proliferation  of such cells at an optimal rate in 
response to IL-2,  and for optimal IL-2 stimulation of im- 
mediate early gene expression (5,  7). 
Several rapid signals that follow IL-2 receptor triggering 
have been identified. Tyrosine phosphorylation of a number 
of substrates, including the serine/threonine kinase Raf-1 (8), 
has been described. The acidic domain of the 3 chain of the 
receptor can physically associate with the lymphoid-specific 
protein tyrosine kinase Lck (9) and IL-2 stimulates  the ac- 
tivity of Lck (9). IL-2 has also been shown to increase the 
level of activated, GTP-bound Ras protein in several  cell types, 
including normal lymphocytes (10), T  cell lines  (11), and 
IL-3-dependent cells expressing IL-2 receptors (12, 13). Both 
the serine-rich and the acidic domains of the IL-2 receptor 
chain are required for this stimulation of Ras GTP accumula- 
tion (13). Similar Ras activation has been observed after cell 
stimulation by IL-3, IL-5, and GM-CSF all of which, like 
IL-2, interact with receptors of the hemopoietin family (14). 
In nonlymphoid cells, activated Ras has been shown to 
stimulate the phosphorylation and activation of members of 
the  mitogen-activated  protein  (MAP)  kinase  family  of 
serine/threonine protein kinases (15). These kinases are acti- 
vated by multiple signaling pathways, including tyrosine ki- 
nase receptors,  receptors coupled to heterotrimeric G pro- 
teins, and activators of protein kinase C (16). MAP kinases 
have been shown to phosphorylate, and activate the transcrip- 
tion factors c-jun  (17), p62 TcF (18), and myc (19), which 
regulate immediate early gene transcription and cell cycle  entry. 
Their activation requires phosphorylation on both threonine 
and tyrosine (20), which can be catalyzed by a single enzyme 
MAP kinase kinase (MAPKK) (21). MAPKK itself is thought 
to be activated by Raf (22). Despite stimulation of Ras acti- 
vation, the expression level of Raf (23) and Raf phosphoryla- 
tion (8, 23), by IL-2,  MAP kinase phosphorylation in re- 
sponse to IL-2 was not observed in either IL-3-dependent 
cells expressing IL-2 receptors (24), or in an IL-2-dependent 
cell line (25). IL-3, IL-5, and GM-CSF have been shown to 
stimulate MAP kinase phosphorylation and activation (26). 
Here we report that IL-2 does stimulate rapid, sustained phos- 
phorylation and activation of Erk2, the 42-kD member of 
the MAP kinase family, in IL-3-dependent cells expressing 
either high, or intermediate affinity IL-2 receptors. Erk2 stim- 
ulation is necessary but  not  suffident for  stimulation of 
proliferation  of these cells. 
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Recombinant  human  IL-2 was  purchased  from  Eurocetus 
(Harejidd, UK) and PMA from Sigma Immunochemicals (St. Louis, 
MO). Conditioned  medium from transfected plasmacytoma cells 
(27) was used as a source of IL-3. 2RB anti-human  II~2 receptor 
chain antibody was a gift from Dr.  M. Kamio (Kyoto Univer- 
sity, Kyoto, Japan), TAC anti-human  IL-2 receptor cr chain anti- 
body was a gift from Professor T. Waldmann (National Institutes 
of Health,  Bethesda, MD), and rapamycin was a gift from Dr. B. 
Weston  (Smith Kline Beecham, London,  UK). 
Cell Lines.  BAF3  calls (28) and their derivatives were cultured 
in DMEM with 10% fetal bovine serum and 0.1% Ib3 conditioned 
medium,  at a density below 4  ￿  10  s cells/ml in a 10% CO2 hu- 
midified incubator. BOE9 and W4E9 ceils were constructed as pre- 
viously described (29). P75 S mutant  cells were constructed  as 
follows: a BamHI fragment  of the Ib2 receptor ~  chain cDNA 
(gift of Professor T. Taniguchi, Osaka University, Osaka, Japan) 
was inserted in pUC18/13 (30). p75 pUC18/13 was digested with 
Sad and AflII, filled in with T4 DNA polymerase and religated. 
The resulting BamHI fragment was ligated into the retroviral vector 
pBABE Puro (31) which was transfected into 92 packaging calls 
(32). Supernatant  from these cells was used to infect BAF3 cells, 
which were then selected in 4/~g/ml puromycin (Sigma). Bc12-15- 
p75-1 cells were constructed  by infecting Bc12-15 cells (33) with 
an identical recombinant retrovirus encoding wild-type p75. Prolifer- 
ation  and  cell cycle analyses were  performed  as  previously de- 
scribed (33). 
Erk2 Measurement.  Samples  were prepared by washing 4  x  106 
cells per determination  twice in DMEM/10% fetal bovine serum, 
then resuspending them in 50 #1 and pretreating  as described. A 
further  50 #1 of the same medium containing  cytokine was then 
added and the cells were incubated for the time indicated at 37~ 
in a 10% CO2 humidified  incubator.  1 ml of ice-cold PBS was 
then added and the cells were pdleted by centrifugation  for 30 s 
at 6,500 rpm in a microfuge. Cell extracts were prepared as previ- 
ously described (15). Western blots and immunoprecipitations using 
the Erk2-specitlc antiserum  122 were performed as previously de- 
scribed (15, 34) except that 50/~g of protein was immunoprecipi- 
tated and the protease inhibitors  used were 1/~g/ml antipain,  1 
/zg/ml elastinal, 1/~g/ml leupeptin,  5/xg/ml aprotinin,  2 #g/ml 
pepstatin  A,  and 0.5 mM PMSF. 
Results and Discussion 
Stimulation of  Erk2 Kinase Activity by 11..-2.  The establish- 
ment of derivatives of the murine  IL-3-dependent cell line 
BAF3 which express either high or intermediate affinity, IL-2 
receptors, by expression of human ~ chain, or ot and B chains, 
of the IL-2 receptor, has been described previously (29). The 
cell line expressing intermediate  affinity receptors (BOE9) 
proliferated half maximaUy in response to 50 pM IL-2, whereas 
W4E9,  which expresses high  affinity receptors,  responded 
half maximally  to 3 pM  IL-2 (29).  These IL-3--dependent 
cells therefore respond  at lower levels  of IL-2 receptor oc- 
cupancy than activated primary T  ceils. Fig. 1 A  shows that 
in both BOE9 and W4E9 cells,  IL-2 could stimulate Erk2 
phosphorylation,  as monitored by reduced mobility on an 
SDS polyacrylamide gel (15). This increase in Erk2 phosphory- 
lation was paralleled by an increase in Erk2  kinase activity 
(Fig.  1 B). Stimulation was rapid,  being maximal within 5 
rain,  and sustained being detectable after 20 min in BOE9 
Figure  1.  Time  course of Erk2 stimulation by 1I.,2. BOE9 cells, ex- 
pressing the p75 B chain of the ID2 receptor (p75), and W4E9 cells, ex- 
pressing the p75 B chain and p55 ot chains (p75/p55), were exposed  to 
250 nM Ib2 for the time indicated (rain) or 5% I1.,3  conditioned  medium 
(c) for 10 min. Erk2 gel mobility  (A) and kinase activity  were then deter- 
mined. (A) Position of the 42-kD unphosphorylated Erk2; (B) position 
of the myelin basic protein kinase substrate (mbp). 
cells and 30 min in W4E9 cells (Fig.  1, A  and B). Sustained 
MAP kinase activation has been correlated with the ability 
of factors to stimulate DNA  synthesis (35).  As previously 
reported (26), IL-3 also stimulated MAP kinase phosphory- 
lation  and activity (Fig.  1, A  and B).  Quantitation  of the 
kinase assay of Fig. 1 B showed a 16-fold activation of kinase 
activity by IL-2, after 5 min, in both BOE9 and W4E9 cells, 
compared  with  20-40-fold  activation  observed with  IL-3. 
Stimulation  of Erk2  phosphorylation  by IL-2,  but  not by 
IL-3, could be inhibited in W4E9 cells by a combination of 
anti-c~  and anti-~  chain  antibodies  (data not  shown). 
The level of IL-2 required to stimulate Erk2 activity half 
maximally was somewhat higher than that required to stimu- 
late proliferation of the two cell lines.  Fig. 2 shows that  12 
nM IL-2 stimulated half-maximal Erk2 activation in BOE9 
cells, compared with 50 pM required for half-maximal  prolifer- 
ation. W4E9 cells required 80 pM IL-2 for half-maximal Erk2 
stimulation, compared with 3 pM required for proliferation. 
Thus,  the level of occupancy of either intermediate or high 
affinity IL-2 receptors that led to stimulation of Erk2 activity 
was higher than that required for stimulation of proliferation. 
Erk2 Stimulation Is Necessary  for Optimal Stimulation of  Prolifer- 
ation by 11..-2.  To further investigate the role of Erk2 phos- 
phorylation in the stimulation of cell proliferation by IL-2, 
we constructed a cell line expressing the IL-2 receptor ~ chain 
deleted in a serine-rich region of the cytoplasmic tail. Surface 
expression of the mutant/~ chain was confirmed by staining 
with the mAb 2RB (data not shown). Fig. 3 A  shows that 
IL-2 was unable to stimulate Erk2 phosphorylation in cells 
expressing this mutant receptor and, as previously described 
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Erk2 kinase activation  by Ib2. (A) 
BOE9 cells ~75) were exposed to 
Ib2 at 2,500 nM (lane 1), 250 nM 
(lane 2), 25 nM (lane 3), 7.9 nM 
(lane 4), 2.5 nM (lane 5), 790 pM 
(lane 6), none (lane 7), and 5% 
IL-3 (lane c).  W4E9 cells (t,75/ 
p55)  were  exposed  to  Ib2  at 
2.5 nM (lane I), 250 pM (lane 2), 
79 pM (lane 3),  25 pM (lane 4), 
7.9 pM (lane 5), 2.5 pM (lane 6), 
none (lane 7), and 5% Ib3 (lane c) 
for 10 min.  Erk2 kinase activity 
was then determined.  The posi- 
tion of the myelin basic protein 
kinase substrate (mbp) is indicated. 
(B) Quantitation  of the data of A. 
(6), was also unable to stimulate cell proliferation. The effect 
of prolonged cytokine removal upon IL-2 ability to stimu- 
late Erk2 phosphorylation was then investigated using a cell 
line Bd2-15-p75-1.  These cells express both the human Bd2 
oncogene product and  the ~  chain of the IL-2 receptor. 
Removal of IL-3 or IL-2 from such cells results in a popula- 
tion that remains viable, but arrested in the G1 phase of the 
cell cycle (33). This allows the cells to be starved of cytokine 
without complication of experiments by the onset of apop- 
tosis. Removal of cytokine from these cells does not affect 
the level of expression of the IL-2 receptor ~ chain (data not 
shown). Fig. 3 B demonstrates that 24 h after IL-3 removal 
from these cells, IL-2 and IL-3 show a reduced ability to stimu- 
late rapid Erk2 phosphorylation, the IL-2 response being lost 
earlier. In cells starved of IL-3, IL-3 or IL-2 readdition was 
unable to stimulate DNA synthesis (Fig.  3 B).  The extent 
of downregulation of DNA synthesis stimulation was iden- 
tical to the decrease in Erk2 stimulation (Fig.  3 B).  Thus, 
in both cells expressing a mutant IL-2 receptor and in 24-h 
starved cells, the loss of rapid IL-2 stimulation of Erk2 was 
correlated with a loss of IL-2 stimulation ofceU proliferation. 
Erk2 Stimulation Is Not Su~cient for,Stimulation  of Prolifera- 
tion.  To examine whether Erk2 stimulation was suf~cient 
to stimulate proliferation of these cells, they were treated with 
tetradecanoyl phorbol acetate (TPA), an activator of protein 
kinase C  that has been shown to activate MAP kinases in 
other calls. TPA stimulated Erk2 in W4E9 ceils to a similar 
level as IL-2 and IL-3, as ascertained both by reduced gel mo- 
bility (Fig. 4 A) and increased kinase activity (data not shown). 
However,  TPA failed to stimulate proliferation of the same 
cells (Fig. 4 A). The effect of the macrocyclide, immunosup- 
pressive agent rapamycin on IL-2 stimulation of Erk2 activity 
and proliferation was then monitored. Fig. 4 B shows that 
rapamycin had no effect on the stimulation of Erk2 phos- 
phorylation by IL-2 or IL-3 in W4E9 cells. It also did not 
inhibit IL-2 or IL-3 stimulation of Erk2 activity (data  not 
shown), However, rapamycin inhibited IL-2 and IL-3 stimu- 
lation of DNA synthesis in these cells, without affecting pres- 
ervation of cell viability (Fig. 4 B). These data demonstrate 
that stimulation of Erk2 activity alone is not suflficient to 
trigger cell proliferation in the BAF3 cell line. Furthermore, 
it can be concluded that IL-2 and IL-3 must stimulate an 
additional, rapamyein-sensitive pathway as well as Erk2, when 
they stimulate cell proliferation. 
The molecular pathway by which triggering of the IL-2 
receptor leads to stimulation of Erk2 remains to be deter- 
mined. Activated Ras has been shown to stimulate Erk2 in 
fibroblasts,  at least partly by a protein kinase C-dependent 
pathway (15). A similar mechanism  might apply to IL-2, which 
does stimulate Ras.GTP accumulation in IL-3-dependent cells 
expressing IL-2 receptors (12, 13). However, IL-2 stimula- 
tion of cell proliferation can occur in the absence of protein 
kinase C  (36). The fact that cells become refractory to IL-2 
stimulation of Erk2 after prolonged cytokine removal, may 
explain the discrepancy between the stimulation reported here 
and the previous report that IL-2 was unable to stimulate 
MAP kinase in similar cells (24). The cytokine-deprived  cells 
retain IL-2 receptor and Erk2 expression,  and should there- 
1431  Perkins et al.  Brief Definitive  Report Figure  3.  Erk2 stimulation is necessary  for stimulation of proliferation. (A, left) Parental BAF3 cells, cells expressing the 11:2 receptor 3 chain p75 
lacking the serine-rich region ~75s) and BOE9 cells ~75) were exposed to no factor (lane I), 2,500 nM I1:2 (lane 2),  or 5% I1:3 (lane 3) for 10 
min. Erk2 mobility was then measured. (A, right) Proliferation of the same cells exposed to no factor (lane I), 25 nM IL-2 (lane 2), or 1% 11:3 (lane 
3) for 24 h, then pulsed with pH]TdR for 4 h. (B, left) Bc12-15-p75-1 cells were deprived of I1:3 for 0,  1, 2, or 3 d, as indicated. They were then 
exposed to no factor, 2,500 nM I1:2 or 5% I1:3, as indicated, for 10 min, and Erk2 mobility was measured. (B, right) Bd2-15-p75-1 cells, deprived 
of I1:3 for 0,  1, 2, or 3 d, as indicated, were exposed to no factor, 250 nM IL-2, or 1% I1:3 in/the  presence of [3H]TdR for 24 h. 
fore be useful tools in the identification  of key components 
on the signaling pathway between receptor and kinase. The 
fact that rapamycin inhibits IL-2 stimulation of proliferation, 
without  affecting  MAP  kinase  activation,  suggests  that  a 
second, rapamycin-sensitive pathway is also required for IL-2 
stimulation of proliferation. This probably involves stimula- 
tion of the serine/threonine kinase p70 $6 kinase, the stimu- 
lation of which by IL-2 (24,  25) is inhibited  by rapamycin. 
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1432  11:2 Stimulation of Erk2 Figure  4.  Erk2 stimulation is not suf~cient for stimulation of proliferation. (-4, left) W4E9 cells were exposed to PMA at 100 nM (lane I), 10 
nM (lane 2),  1 nM (lane 3), 100 pM (lane 4), 10 pM (lane 5), 1 pM (lane o  0, no factor (lane 7), or 5% II:2 (lane c) for 10 rain. Erk2 mobility was 
then measured. (A, right) W4E9 cells were exposed to the concentration of PMA indicated, or 1% 11:3 for 24 h, then pulsed with [3H]TdR for 4 
h. (B, left). Control W4E9 cells (-), or cells preincubated with 200 ng/ml rapamycin (+), were exposed to no factor (lane I), 25 nM 11:2 (lane 2), 
or 5% I1:3 (lane 3) for 10 min. Erk2 mobility was then determined. (B, right). W4E9 cells were incubated with 2.5 nM I1:2 or 1% 11:3 in the absence 
or presence of 10 ng/ml rapamycin, as indicated, for 24 h. Cell viability and [3H]TdR incorporation after a 4-h pulse were then measured. 
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